Aghazadeh Behzad purchased $36.3M of SCTX (indirect holdings)
Aghazadeh Behzad purchased 2,391,238 indirectly-held shares of Scribe Therapeutics, Inc. (SCTX) at an average of $15.16 ($15.00–$22.31, $36.26M total) across 3 trades over 2026-07-24 to 2026-07-28.
How this was made
The 30-second read
Why it matters
Traders may view the $36.26M open-market buy as a positive sentiment input, but the article contains no new operational or financial information to reprice fundamentals.
Market read
Large insider buying can attract short-term attention, but without new company catalysts it is unlikely to drive a sustained repricing.
What to watch
The filing does not state intent, rationale, or whether the insider already held substantial exposure; price range ($15 to $22.31) suggests trades across varying market conditions.
Background
This is an SEC Form 4 insider transaction disclosure for Scribe Therapeutics, Inc. (SCTX).
Ticker impact
Scribe Therapeutics disclosed a director/10% owner open-market purchase totaling $36.26M via Form 4, with 2.39M shares bought in late July.
Near-term impact is likely limited, though it can support sentiment if traders treat it as a confidence signal.
Form 4 provides transaction details (size, dates, price range) but no accompanying company-specific catalyst like earnings, trial results, or financing.
Market effects
No sector-wide read-across is provided beyond a single biotech insider transaction.
None indicated.
None indicated.
Counterpoint
A large indirect purchase can reflect liquidity planning or pre-existing arrangements rather than a new bullish thesis, especially without a 10b5-1 plan.
Key entities
- issuerScribe Therapeutics, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderAghazadeh Behzad
Director and 10% owner who purchased shares indirectly in late July 2026.
